Conversely however, Guellec et al26 described 2‐year overall survival rates for UPS with MDM2 amplification, conventional DDLPS, and UPS without MDM2 expression of 93.3%, 90.7%, and 73.9%, respectively, thus indicating that MDM2 amplified sarcomas showed a better prognosis. The gene discussed is MDM2; the disease is sarcoma.